Business context and reporting period
Entity note: The supplied filing is for Torchmark Corporation, not an issuer named Globe Life Inc. It is a Form 10-Q for the quarter ended September 30, 2014, filed November 7, 2014. The filing describes an insurer focused on individual life and supplemental health insurance.
Financial performance and position
Dollar amounts below are rounded to millions unless stated otherwise.
| Metric | Q3 2014 | Q3 2013 | Nine months 2014 | Nine months 2013 |
|---|---|---|---|---|
| Total revenue | $967.0 | $932.8 | $2,968.1 | $2,841.3 |
| Net income | $132.4 | $132.1 | $396.2 | $385.7 |
| Diluted EPS | $1.00 | $0.95 | $2.97 | $2.75 |
| Cash from operations | Not separately presented | Not separately presented | $644.4 | $771.1 |
- Premiums: Nine-month life premiums rose 4% to $1.473 billion; health premiums rose 5% to $931.5 million as reported, including Medicare Part D risk-sharing adjustments. Total premiums increased 4% to $2.405 billion.
- Underwriting: Nine-month life underwriting income increased 3% to $420.6 million, with a 29% margin. Non-Part D health underwriting income rose 1% to $148.5 million, with a 23% margin. Medicare Part D underwriting income declined 10% to $22.7 million; its margin fell to 9% from 11%.
- Investment earnings: Net investment income increased 3% to $546.0 million for nine months. Management’s segment measure, excess investment income, rose 3% to $169.5 million, or 9% per diluted share to $1.27. The fixed-maturity portfolio’s average effective yield was 5.91%, versus 5.95% a year earlier.
- Debt and liquidity: At September 30, cash and short-term investments totaled approximately $146 million. Short-term debt was $290.4 million and long-term debt $991.8 million. The company had a $750 million credit facility, with $198 million of letters of credit and $261.5 million of remaining availability. Interest coverage was 10.9 times for the nine-month period.
- Capital and investments: Total assets were $19.871 billion and shareholders’ equity $4.530 billion. Fixed maturities had $14.153 billion fair value and a $1.425 billion net unrealized gain. About 96% of the portfolio was investment grade, with an average rating of A-. These unrealized gains materially boosted reported equity.
Material changes versus the prior comparable period
- For nine months, revenue increased about 4% and net income 3%; diluted EPS rose 8%, helped by a lower share count following repurchases. Q3 net income was nearly flat year over year, while diluted EPS increased 5%.
- Operating cash flow declined $126.7 million to $644.4 million, primarily because of higher Medicare Part D receivables from CMS for costly Hepatitis C drug claims and higher-than-expected generic drug costs.
- Part D premiums increased 14% and net sales nearly tripled, partly due to automatic enrollees and employer-group activity, but segment underwriting income declined as costs rose.
- Shareholders’ equity increased from $3.776 billion at year-end 2013, largely reflecting after-tax unrealized investment gains; the company repurchased 5.5 million shares for $287.7 million using excess cash flow.
- Commercial paper rose to $290.5 million from $229.1 million at December 31, 2013. Long-term debt was broadly unchanged.
Outlook, risks, contingencies and unusual items
- Medicare Part D outlook: Management expected 2014 full-year Part D margins of approximately 6%–9% of premium, citing Hepatitis C drug costs not anticipated in pricing. It expected less volatility and a return to higher historical margins in 2015 after repricing, while anticipating fewer automatic enrollees and lower premium income. Government program and regulatory changes could alter this outlook.
- CMS reimbursement timing: Management estimated delayed reimbursement for unusually high Part D claims would reduce investment income by approximately $4 million in 2014 and $6 million in 2015.
- Other items: Nine-month results included $8.2 million of administrative settlements for older death claims, a $3.7 million net accrual for certain litigation, and $1.3 million received in investment-litigation settlement. Realized investment gains were $15.7 million pretax for nine months. Medicare Part D interim accounting differences reduced earnings by approximately $11 million after tax relative to management’s segment presentation; the filing said the difference was expected to eliminate by year-end.
- Capital and market risks: S&P revised its outlook on Torchmark to negative during Q3; management said it did not expect the action to change the repurchase program. Risks cited include interest rates, investment issuer credit, insurance claims and lapses, pricing competition, regulatory changes, and litigation. Management reported no material change in market-risk exposure or risk factors.
- Legal contingency: Insurance subsidiaries were subject to unclaimed-property audits involving 47 states. No state assessment or liability had been indicated, and management could not estimate a range of potential losses, penalties, or escheatment payments. Management did not expect other litigation to have a material adverse effect, while noting punitive-damage outcomes are uncertain.
- Guidance limitation: The filing gives the Part D outlook above but does not provide a clear consolidated earnings or revenue forecast.
Most important facts for investors to verify
- Confirm the issuer and ticker: the provided filing names Torchmark Corporation, despite the request metadata naming Globe Life Inc.
- Track Part D claims, CMS receivables and collections, and whether actual full-year margins fall within management’s 6%–9% estimate.
- Assess the sustainability of operating cash flow and liquidity given the Part D reimbursement delay and increased commercial paper balance.
- Separate recurring earnings from realized investment gains, administrative settlements, litigation items, and Part D interim accounting adjustments.
- Evaluate investment credit quality and interest-rate sensitivity, including the size of the unrealized-gain contribution to reported equity.
- Monitor the unclaimed-property audits, S&P outlook, and the company’s capital and share-repurchase decisions.